Apr 8, 2021

Featuring perspectives from Dr Kristen K Ciombor and Prof Eric Van Cutsem, including the following topics:

• Introduction (0:00)
• Case: A woman in her mid-60s with microsatellite stable (MSS) right-sided metastatic colorectal cancer (mCRC) with a KRAS G13B mutation and a tumor mutation burden (TMB) of 11 mut/Mb — Warren S Brenner, MD (3:00)
• Case: A woman in her early 60s with microsatellite instability (MSI)-high, TMB-high mCRC who achieves a response to pembrolizumab but experiences pneumonitis — Gigi Chen, MD (10:00)
• Updated results from the Phase III KEYNOTE-177 trial of pembrolizumab and the Phase II CheckMate 142 trial of nivolumab/ipilimumab as first-line therapy for MSI-high/mismatch repair-deficient advanced CRC (16:42)
• Case: A woman in her mid-50s with previously treated mCRC harboring KRAS and BRAF mutations who receives TAS-102/bevacizumab — Justin Peter Favaro, MD, PhD (19:39)
• Case: A woman in her early 70s with MSI-high, PD-L1-positive mCRC harboring BRAF V600E and somatic BRCA1 mutations — Dr Brenner (27:54)
• Efficacy and safety of TAS-102 in combination with bevacizumab as first-line therapy in the Phase II TASCO1 trial for patients with mCRC; utility of ctDNA in mCRC with a BRAF V600E mutation (36:40)
• Case: A man in his mid-60s with asymptomatic, relapsed mCRC and a rising carcinoembryonic antigen level off treatment — Margaret Deutsch, MD (46:35)
• Case: A woman in her early 30s with extensively treated MSS mCRC with no targetable mutations — Mamta Choksi, MD (49:15)
• Emerging clinical trial results and future directions in the management of mCRC (53:27)

CME information and select publications